This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZFGN Zafgen (ZFGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Zafgen Stock (NASDAQ:ZFGN) Get Zafgen alerts:Sign Up Key Stats Today's Range$5.05▼$5.3550-Day Range$0.99▼$25.0652-Week Range$0.62▼$2.76Volume1.32 million shsAverage Volume360,199 shsMarket Capitalization$190.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. Read More Receive ZFGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zafgen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZFGN Stock News HeadlinesTokyo Steel Manufacturing Co Ltd 5423May 16, 2024 | morningstar.comMGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030April 9, 2023 | marketwatch.comSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.June 16 at 1:00 AM | Weiss Ratings (Ad)Zafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug ResultsFebruary 26, 2023 | thestreet.comZafgen (ZFGN) Stock Surges on Positive Obesity Drug TrialJanuary 13, 2023 | thestreet.comFood and drink in a castleNovember 8, 2022 | bbc.co.ukLRMR Larimar Therapeutics, Inc.September 30, 2022 | seekingalpha.comForm 424B5 Larimar Therapeutics, - StreetInsider.comSeptember 14, 2022 | streetinsider.comSee More Headlines ZFGN Stock Analysis - Frequently Asked Questions How were Zafgen's earnings last quarter? Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings data on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.19). What other stocks do shareholders of Zafgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zafgen investors own include Bristol Myers Squibb (BMY), Energy Transfer (ET), BlackRock (BLK), TG Therapeutics (TGTX) and SCYNEXIS (SCYX). Company Calendar Last Earnings3/05/2020Today6/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZFGN CIK1374690 Webwww.zafgen.com Phone617-622-4003FaxN/AEmployees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.34% Return on Assets-34.55% Debt Debt-to-Equity Ratio0.26 Current Ratio6.56 Quick Ratio6.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book3.77Miscellaneous Outstanding Shares37,470,000Free FloatN/AMarket Cap$190.72 million OptionableNot Optionable Beta0.27 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ZFGN) was last updated on 6/16/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...Wall Street Logic | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zafgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
